🔎 Trials Near Me

Home › Kanser sa Prostate › Kansas

Pag-aaral pangklinika para sa Kanser sa Prostate sa Kansas

21 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa Kansas.

Mga Lungsod sa Kansas

Opisyal na teksto ng pag-aaral (English)

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • Central Care Cancer Center - Garden City, Garden City
  • Mercy Hospital Pittsburg, Pittsburg
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Nob 13, 2026 · NCT04423211

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • at 4 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT03866382

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

  • Kansas University Cancer Center, Kansas City
Nagre-recruitPhase 2
Edad 18 pataas · Kalalakihan · Na-update Nob 5, 2026 · NCT07745361

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Veteran Administration Eastern Kansas Healthcare, Leavenworth
  • at 4 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT05334069

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

  • University of Kansas Cancer Center, Kansas City
  • The University of Kansas Cancer Center - Olathe, Olathe
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • at 2 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06632977

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

  • HaysMed, Hays
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • at 4 pa
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Nob 3, 2026 · NCT06931340

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • University of Kansas Medical Center, Kansas City
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Nob 2, 2026 · NCT07581184

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • University of Kansas Cancer Center, Kansas City
  • Lawrence Memorial Hospital, Lawrence
  • The University of Kansas Cancer Center - Olathe, Olathe
  • at 3 pa
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Okt 23, 2026 · NCT05946213

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • University of Kansas Medical Center, Westwood
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Okt 20, 2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • University of Kansas Hospital, Kansas City
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Kalalakihan · Na-update Okt 15, 2026 · NCT06855277

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  • University of Kansas Cancer Center, Kansas City
  • Olathe Health Cancer Center, Olathe
  • University of Kansas Cancer Center-Overland Park, Overland Park
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Okt 8, 2026 · NCT03678025

DESTINY-PANTUMOUR04

  • Research Site, Topeka
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • University of Kansas Hospital, Kansas City
Nagre-recruitPhase 2/3
Edad 18 hanggang 100 · Kalalakihan · Na-update Set 22, 2026 · NCT06780670

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • Wichita Urology Group, Wichita
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Set 11, 2026 · NCT06056830

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

  • University of Kansas Health System, Kansas City
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT03802851

Integrated Cancer Repository for Cancer Research

  • Saint Luke's Cancer Instititute - South, Overland Park
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

TERPS Trial for de Novo Oligometastic Prostate Cancer

  • KU Medical Center- Cancer Center, Kansas City
Nagre-recruitPhase 2
Edad 18 pataas · Kalalakihan · Na-update Hun 3, 2026 · NCT05223803

Study of AZD0754 in Participants With Metastatic Prostate Cancer

  • Research Site, Westwood
Nagre-recruitPhase 1/2
Edad 18 hanggang 130 · Kalalakihan · Na-update Peb 23, 2026 · NCT06267729

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  • Wichita Urology Group, Wichita
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Peb 4, 2026 · NCT04729114

Vitamin D for Prostate Endocrine Therapy

  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Cancer Center-Overland Park, Overland Park
  • University of Kansas Health System Saint Francis Campus, Topeka
  • at 1 pa
Nagre-recruitPhase 3
Edad 50 pataas · Kalalakihan · Na-update Ene 15, 2026 · NCT05838716

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.